|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:anticoagulant
gptkb:serine_protease
|
|
gptkbp:approvedBy
|
gptkb:Japan
gptkb:South_Korea
|
|
gptkbp:ATCCode
|
B01AD10
|
|
gptkbp:CASNumber
|
82956-11-4
|
|
gptkbp:chemicalFormula
|
C19H17N5O2
|
|
gptkbp:developedBy
|
gptkb:Japan
|
|
gptkbp:discoveredBy
|
gptkb:Ono_Pharmaceutical
|
|
gptkbp:eliminationHalfLife
|
approximately 8 minutes
|
|
gptkbp:hasInChIKey
|
QXWYNZJAWZBGBN-UHFFFAOYSA-N
|
|
gptkbp:hasSMILES
|
CCOC(=O)C1=CC=C(C=C1)C(=O)NC2=CC3=C(C=C2)C=CC=C3N=C(N)N
|
|
gptkbp:hasUNII
|
U5Q7ZL0E5Y
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nafamostat
|
|
gptkbp:investigatedBy
|
gptkb:COVID-19
|
|
gptkbp:IUPACName
|
ethyl 4-(6-guanidino-2-naphthylcarbamoyl)benzoate
|
|
gptkbp:KEGGID
|
D08210
|
|
gptkbp:legalStatus
|
prescription only (Japan, South Korea)
|
|
gptkbp:marketedAs
|
gptkb:Futhan
|
|
gptkbp:mechanismOfAction
|
inhibits serine proteases such as thrombin, plasmin, and trypsin
|
|
gptkbp:metabolism
|
plasma esterases
|
|
gptkbp:molecularWeight
|
347.37 g/mol
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2103837
4413
DB12530
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
anaphylaxis
thrombocytopenia
leukopenia
hyperkalemia
|
|
gptkbp:usedFor
|
anticoagulation in extracorporeal circulation
treatment of acute pancreatitis
|
|
gptkbp:bfsParent
|
gptkb:LianBio
|
|
gptkbp:bfsLayer
|
7
|